Related Experiment Video
Updated: Jun 21, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Evaluation of Drug Resistance in the Tamoxifen-treated MKN-45 Gastric Cancer Cell Line via the Epithelial-mesenchymal
Zeinab Mahdian1,2, Mahdi Pouramir3,1, Hassan Akrami4
1Department of Clinical Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Abstract:
One of the major challenges in gastric cancer (GC) chemotherapy is the phenomenon of multi-drug resistance (MDR). The epithelial-mesenchymal transition (EMT) and its key molecules, transforming growth factor-β (TGFβ) and SMAD2, play a central role in MDR occurrence. Tamoxifen (TAM), a triphenylethylene derivative, can overcome MDR in human gastric cancers. The aim of this study was to investigate the effect of TAM on 5-FU resistance of GC by suppressing the TGFβ1/SMAD2 signaling pathway and EMT. The MKN-45 cell line was subjected to treatment with 5-FU, TAM and a combination of both. The MTT assay was used to investigate the cytotoxic effects of 5-FU and TAM, and the DNA laddering technique was used to assess DNA fragmentation and apoptosis. Real-time RT-PCR examined the change in gene expression in EMT-related genes (SNAI2, VIM, TGFβ1 and SMAD2). The results of the present study indicated that not only TAM treatment significantly decreased the IC50 of 5-FU (P≤0.05), but also the addition of TAM to 5-FU induced apoptosis in the MKN-45 cell line. Treatment with TAM and 5-FU significantly inhibited TGFβ1 and TGFβ1-induced expression of EMT markers (VIM and SNAI2) in MKN-45 cells (P≤0.05). The reduction of TGFβ1 targets downstream of the SMAD2 signaling pathway reversed the process of EMT and significantly increased the sensitivity of MKN-45 cells to 5-FU. The results of the present study suggested that reversal of EMT-mediated MDR via the TGFβ1/SMAD signaling pathway using TAM may be a potential new therapeutic strategy to overcome chemoresistance to 5-FU during GC chemotherapy.
Insights
Tamoxifen (TAM) overcomes 5-fluorouracil (5-FU) resistance in gastric cancer by suppressing epithelial-mesenchymal transition (EMT) and the TGFβ1/SMAD2 pathway. This strategy enhances chemotherapy effectiveness and induces apoptosis in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multi-drug resistance (MDR) is a major challenge in gastric cancer (GC) chemotherapy.
- Epithelial-mesenchymal transition (EMT), driven by TGFβ1/SMAD2, is crucial for MDR.
- Tamoxifen (TAM) shows potential in overcoming MDR in GC.
Purpose of the Study:
- To investigate TAM's effect on 5-FU resistance in GC.
- To determine if TAM suppresses the TGFβ1/SMAD2 pathway and EMT.
- To assess TAM's impact on apoptosis and gene expression in GC cells.
Main Methods:
- Utilized the MKN-45 GC cell line.
- Administered 5-FU, TAM, and combination treatments.
- Assessed cytotoxicity (MTT assay), apoptosis (DNA laddering), and gene expression (real-time RT-PCR) of EMT markers (SNAI2, VIM, TGFβ1, SMAD2).
Main Results:
- TAM significantly reduced the IC50 of 5-FU (P≤0.05).
- Combined TAM and 5-FU treatment induced apoptosis in MKN-45 cells.
- TAM and 5-FU inhibited TGFβ1 and EMT markers (VIM, SNAI2), reversing EMT and enhancing 5-FU sensitivity.
Conclusions:
- TAM reverses EMT-mediated MDR by inhibiting the TGFβ1/SMAD2 pathway.
- This suggests TAM is a potential therapeutic strategy to overcome 5-FU chemoresistance in GC.
- Targeting EMT via TAM offers a novel approach for GC chemotherapy.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

